What were the key takeaways from Bionano Genomics's earnings call?

What guidance did Bionano Genomics's management provide for the next earnings period?

What is the revenue and EPS growth rate for Bionano Genomics year over year?

What is Bionano Genomics's gross profit margin?

What were the key takeaways from Bionano Genomics’s earnings call?

What is Bionano Genomics's latest dividend and current dividend yield?

What factors drove the changes in Bionano Genomics's revenue and profit?

What does Bionano Genomics do and what are its main business segments?

- **Strategic Shift Success**: Routine use customers drive 83% of consumables revenue, with 60 validated sites averaging $131,000/year.
- **Profitability Improvement**: Non-GAAP gross margin expanded to 47% (vs. 35% in 2024), operating expenses reduced 47% to $36.6 million.
- **Reimbursement Catalyst**: Hematologic malignancy CPT code pricing increased 47% to $1,853.22, supporting 2026 growth.
- **Operational Scale**: Radboud University Medical Center processing 3,000 OGM samples/year, demonstrating academic adoption at scale.
- **2026 Outlook**: $30-33 million revenue target (+5-16%), driven by reimbursement expansion and existing customer utilization.

**【CEO Opening Remarks】**
- Announced strategic shift in 2024 to focus on profitable growth from high-volume users, replacing aggressive installed base expansion.
- Highlighted four strategic pillars: supporting installed base, increasing OGM utilization, building reimbursement support, and improving profitability.
- Routine use customers (40% of installed base) generate 83% of consumables revenue, with average revenue per customer doubling at $89,000/year.

**【CFO Financial Commentary】**
- Q4 2025 revenue: $8 million (-3% YoY), at high end of guidance range.
- Full-year 2025 revenue: $28.5 million (-7% YoY), with core revenue down 2% excluding clinical services.
- Flowcell sales: 30,171 units (-0.4% YoY), constrained by supply in Q4.
- Non-GAAP gross margin: 47% YoY (vs. 35%), operating expenses: $36.6 million (-47% YoY).
- Cash position: $29.6 million, with debt expected to be retired in May 2026.

**【CEO Strategic Update】**
- 60 validated routine use customers account for 56% of consumables revenue, averaging $131,000/year.
- 55 potential future validators and 15 non-validator routine users.
- VIA software expansion: 136 Q4 publications (+25% YoY), 450+ annual publications (+28% CAGR since 2020).
- Reimbursement progress: new CPT code for constitutional disorders priced at $1,263.53, hematologic malignancy code increased 47% to $1,853.22.
- Bionano Symposium 2026: 1,250 registrants from 73 countries, showcasing OGM adoption at scale (e.g., Radboud University Medical Center processing 3,000 samples/year).

**【Q&A Highlights】**
- 2026 system installations expected to match 2025 levels (32 units), but focus on increasing usage from existing customers.
- Flowcell sales growth constrained by Q4 supply issues, but 2025 routine use customers showed 5% YoY growth.
- 2026 revenue guidance: $30-33 million (+5-16%), driven by higher CPT code pricing and expanded OGM utilization.
- 2026 Q1 guidance: $6.5-6.7 million (flat to +3%), reflecting seasonal patterns.

Bionano Genomics, Inc. (BNGO) Q4 2025 Earnings Call Transcript

- **Revenue Growth**: Q3 2025 revenue up 21% YoY to $7.4M. Core business momentum with 12% YoY growth in recurring consumables. 
- **Profitability Expansion**: 46% gross margin (vs 26% prior year) and 40% opex reduction. 
- **Strategic Focus**: Shifting to a high-margin, predictable model with routine users. 
- **Market Expansion**: Japanese market potential and reimbursement progress. 
- **Financial Discipline**: $31.8M cash runway. 
- **Growth Drivers**: 7% YoY flow cell growth and 15% consumables revenue expansion.

**【CEO Summary Section】**
- Q3 2025 revenue reached $7.4 million, up 21% YoY. Core revenue (excluding discontinued services) grew 12% YoY. Flow cell sales hit a record 8,390 units (+7% YoY), driven by routine user utilization. Non-GAAP gross margin improved to 46% from 26% in Q3 2024. Operating expenses decreased 40% YoY to $9.7 million. The company reiterates 2025 full-year revenue guidance of $26-30 million.

**【CFO Financial Commentary】**
- Strong cash position of $31.8 million post $10M equity raise. Non-GAAP metrics show improved profitability: 46% gross margin (vs 22% in Q1 2023) and 72% product mix from consumables/software (vs 62% in 2024). The company targets maintaining flat operating expenses while investing strategically.

**【Q&A Highlights】**
- **Utilization Targets**: CEO expects routine users to move from 4-40 samples/week to a mid-range target of ~20 samples/week. 
- **Japanese Market**: 1 installed system serving academic and pharma customers. Growth potential in cell therapy applications. 
- **Reimbursement Progress**: New CPT code pricing at $1,263.53, higher than legacy microarray codes. 97 new OGM publications in Q3 (+10% YoY).

Bionano Genomics, Inc. (BNGO) Q3 2025 Earnings Call Transcript

- **Strategic Shift Success**: 17% YoY flowcell growth reflects focus on routine users, despite 5% adjusted revenue decline.
- **Profitability Improvements**: 52% non-GAAP gross margin and 53% opex reduction highlight cost-cutting efforts.
- **Product Momentum**: VIA 7.2 expansion and 10,000-genome milestone support OGM adoption; new CPT code for constitutional disorders.
- **Guidance Update**: Raised 2025 installations to 20-25, signaling confidence in routine user growth.

**【CEO Opening Remarks】**
- Announced Q2 2025 revenue of $6.7 million, down 13% YoY (5% adjusted for discontinued services). Highlighted strategic shift to focus on routine OGM users, driving 17% YoY flowcell sales growth.
- Emphasized 4 strategic pillars: support installed base, drive VIA adoption, secure reimbursement, and improve profitability.

**【Financial Performance】**
- Non-GAAP gross margin improved to 52% (vs. 35% YoY), with operating expenses reduced 53% to $8.8 million.
- Installed 7 new systems, bringing total to 378 (net decrease of 1 due to 8 returns). Ended with $27.4 million in cash.

**【Product & Market Updates】**
- Released VIA 7.2, Solve 3.8.3, and Stratys Compute updates, enabling AI-driven workflows for constitutional disorders.
- Reached 10,000 published clinical research genomes and secured a second CPT code for OGM in constitutional disorders.

**【Q&A Highlights】**
- VIA adoption: ~1/3 of OGM systems have VIA, but >80% among routine users. New CPT code may expand reimbursement opportunities.
- System returns: <1% of new installations, driven by research-focused labs. Raised 2025 installations guidance to 20-25 (from 15-20).

Bionano Genomics, Inc. (BNGO) Q2 2025 Earnings Call Transcript

- **Gross margin milestone**: 46% GAAP/Non-GAAP gross margin, up 14-12 pts YoY, driven by cost optimization.
- **Routine user focus**: 80%+ of flowcells sold to high-utilization labs, with 1% YoY volume growth.
- **Clinical validation**: MD Anderson study shows OGM detects 15% of critical variants missed by standard methods.
- **Cash runway stability**: $29.2M cash, extending to Q1 2026 with $3.2M ATM proceeds in Q1.
- **Supply chain resilience**: Minimal direct exposure to trade tensions, but cautious on international customer delays.


**【CEO Strategic Shift Overview】**
- Transitioned from heavy customer acquisition to focusing on routine OGM users, reducing capital sales by 66% YoY.
- Four strategic pillars: support existing users, drive software adoption, expand clinical menus, and improve profitability through cost reduction.

**【Q1 2025 Financial Highlights】**
- Total revenue: $6.5M (26% YoY decline, excluding discontinued clinical services).
- Flowcells sold: 6,994 (-15% YoY, +1% YoY for existing users).
- GAAP & Non-GAAP gross margin: 46% (vs. 32% & 34% YoY).
- Operating expenses: $11.4M GAAP (-66% YoY), $8.5M Non-GAAP (-65% YoY).
- Cash runway extended to Q1 2026 with $29.2M in cash.

**【Strategic Progress】**
- 95 publications (second-highest Q1 on record), including MD Anderson study showing OGM detects 15% of critical variants missed by standard methods.
- 9 new OGM installations (total 379 systems, +9% YoY).
- 80%+ of flowcells sold to routine users, with utilization rates double the average.

**【Q&A Key Takeaways】**
- CPT code adoption: AMA Category 1 code for OGM in hematologic malignancies reduces barriers to reimbursement.
- Supply chain: <10% of inputs sourced outside US; cautious on global trade impacts on international customers.
- Instrument installs: 15-20 systems for 2025, prioritizing routine use sites despite Q1 overperformance.
- Gross margin sustainability: 46%+ expected for 2025, with further upside from scale.


Bionano Genomics, Inc. (BNGO) Q1 2025 Earnings Call Transcript

- **Revenue Resilience**: 2024 product revenue grew 1% to $27M, with 14% consumables growth despite strategic shift away from new instrument sales.
- **Margin Improvement**: Non-GAAP gross margin jumped to 42% in Q4 2024 (from 22% in Q1 2023), reflecting cost optimization and efficiency gains.
- **Strategic Focus**: 118 'routine use' customers drive 80% of consumables revenue; 2025 strategy centers on VIA software adoption and disciplined customer expansion.
- **CPT Code Impact**: New Category 1 CPT code for hematologic malignancies (Jan 2025) positions OGM for broader adoption in clinical workflows.

**【CEO Summary Section】**
- **Q4 2024 Financial Highlights**: Total revenue of $8.2 million (-24% YoY), driven by discontinued clinical services. GAAP gross margin improved to 42% (vs. 23% in Q4 2023). Non-GAAP gross margin also 42% (vs. 24% YoY). Full-year product revenue grew 1% to $27 million, with consumables up 14% and software up 11%. Cash runway extended to Q1 2026 after $10M registered offering and ATM sales.
- **Strategic Shift**: Focused on 118 'routine use' customers (80% of consumables revenue), prioritizing VIA software adoption to streamline workflows and increase sample throughput. 2025 revenue guidance: $29-32 million, with 15-20 new system installations targeting routine use sites.
- **Gross Margin Progress**: Non-GAAP gross margin rose from 22% (Q1 2023) to 42% (Q4 2024), driven by cost reductions and efficiency gains.

**【Q&A Key Takeaways】**
- **Customer Acquisition Strategy**: New customers will be added selectively, focusing on those with low acquisition costs and high utilization potential. Expansion of the 118 routine use group is key, with average revenue per customer ~$85,000-$90,000.
- **Software Impact**: VIA installations grew from 40 to 160 sites, automating variant curation and reporting, enabling labs to process more samples faster. This is expected to drive menu expansion and higher consumables usage.
- **Reimbursement Progress**: AMA's Category 1 CPT code for hematologic malignancies (effective Jan 2025) is being used, with potential for future code expansion. Medicare fee schedule pricing aligns with proprietary PLA codes (~$1,300), though higher rates exist for some applications.
- **Growth Drivers**: Solid tumor applications and cell/gene therapy R&D are emerging opportunities, complementing core hematologic malignancy and constitutional disorder markets.

Actual							-180	-54	-48	-42	-24	-42	-42	-48	-66	-66	-66	-78	-72	-74.4	-193.2	-66.9	-36	-14.4	-31.2	-12.135	-1.15	-2	-2.04	-2.475
Forecast							-129	-52	-31.5	-31.5	-27	-27	-34.545	-39.285	-44.835	-54	-68	-67.4434	-62.7212	-62.5499	-58.1796	-52.2412	-38.6477	-24.918	-11.8513	-5.898	-3.0233	-2.6569	-2.075	-2.475
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-39.53%	-3.85%	-52.38%	-33.33%	+11.11%	-55.56%	-21.58%	-22.18%	-47.21%	-22.22%	+2.94%	-15.65%	-14.79%	-18.95%	-232.08%	-28.06%	+6.85%	+42.21%	-163.26%	-105.75%	+61.96%	+24.72%	+1.69%	0.00%

BNGO

BNGO fundamentals

BNGO Q4 2025 Earnings

Earnings Call

You can ask Aime

BNGO

BNGO fundamentals

BNGO Q4 2025 Earnings

Earnings Call

BNGO Earnings Call Summary for Q4/20254:30 PM on Mar 23, 2026

BNGO Earnings Call Summary for Q3/20254:30 PM on Nov 13, 2025

BNGO Earnings Call Summary for Q2/20254:30 PM on Aug 14, 2025

BNGO Earnings Call Summary for Q1/20254:30 PM on May 14, 2025

BNGO Earnings Call Summary for Q4/20244:30 PM on Mar 31, 2025

You can ask Aime